JP2022545291A5 - - Google Patents

Info

Publication number
JP2022545291A5
JP2022545291A5 JP2022512720A JP2022512720A JP2022545291A5 JP 2022545291 A5 JP2022545291 A5 JP 2022545291A5 JP 2022512720 A JP2022512720 A JP 2022512720A JP 2022512720 A JP2022512720 A JP 2022512720A JP 2022545291 A5 JP2022545291 A5 JP 2022545291A5
Authority
JP
Japan
Prior art keywords
substituted
oxy
pharmaceutical composition
composition according
octan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022512720A
Other languages
English (en)
Japanese (ja)
Other versions
JP7673052B2 (ja
JP2022545291A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048119 external-priority patent/WO2021041616A1/en
Publication of JP2022545291A publication Critical patent/JP2022545291A/ja
Publication of JP2022545291A5 publication Critical patent/JP2022545291A5/ja
Application granted granted Critical
Publication of JP7673052B2 publication Critical patent/JP7673052B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022512720A 2019-08-29 2020-08-27 細菌感染症を処置するためのベータラクタム抗生物質およびアビバクタム誘導体の経口投与される組合せ Active JP7673052B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893612P 2019-08-29 2019-08-29
US62/893,612 2019-08-29
US201962953852P 2019-12-26 2019-12-26
US62/953,852 2019-12-26
PCT/US2020/048119 WO2021041616A1 (en) 2019-08-29 2020-08-27 Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Publications (3)

Publication Number Publication Date
JP2022545291A JP2022545291A (ja) 2022-10-26
JP2022545291A5 true JP2022545291A5 (enExample) 2023-08-31
JP7673052B2 JP7673052B2 (ja) 2025-05-08

Family

ID=72433031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022512720A Active JP7673052B2 (ja) 2019-08-29 2020-08-27 細菌感染症を処置するためのベータラクタム抗生物質およびアビバクタム誘導体の経口投与される組合せ

Country Status (11)

Country Link
US (3) US20210060033A1 (enExample)
EP (1) EP4021443A1 (enExample)
JP (1) JP7673052B2 (enExample)
KR (1) KR20220054364A (enExample)
CN (1) CN114302725A (enExample)
AU (2) AU2020337449A1 (enExample)
BR (1) BR112022001344A2 (enExample)
CA (1) CA3152300C (enExample)
IL (1) IL290260A (enExample)
MX (1) MX2022002537A (enExample)
WO (1) WO2021041616A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses
EP4319760A4 (en) * 2021-04-05 2025-01-08 Qpex Biopharma, Inc. CEFTIBUTENE DOSAGE REGIMEN
JP2024524372A (ja) * 2021-07-01 2024-07-05 キューペックス バイオファーマ， インコーポレイテッド セフチブテンの結晶形態
US20240390335A1 (en) * 2021-11-09 2024-11-28 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Pharmaceutical composition containing beta-lactam compound and use thereof
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
CN116327764B (zh) * 2023-04-06 2024-04-12 浙江医药股份有限公司新昌制药厂 一种高效广谱抗耐药菌的药物组合物及其制备方法和其应用
CN119431373B (zh) * 2024-07-24 2025-08-08 科睿迪(南京)医药科技有限公司 一种β-内酰胺酶抑制剂及其用途
CN122079989A (zh) * 2024-09-30 2026-05-26 科睿迪(南京)医药科技有限公司 二氮杂二环类β-内酰胺酶抑制剂及其应用
WO2026104587A1 (en) 2024-11-13 2026-05-21 Adjutec Pharma As Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046845A1 (en) * 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
MX2020004071A (es) 2017-10-02 2020-07-28 Arixa Pharmaceuticals Inc Derivados de aztreonam y usos de los mismos.

Similar Documents

Publication Publication Date Title
CN1188422C (zh) 钙(3s)四氢－3－呋喃基(1s,2r)－3－[[(4－氨基苯基)磺酰基](异丁基)氨基]－1－苯甲基－2－(膦酰氧基]丙基氨基甲酸酯
CA2661166C (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
JP6359971B2 (ja) イバブラジン塩酸塩の形態ｉｖ
JP2020519684A5 (enExample)
CA3195789A1 (en) Solid state forms of resmetirom
PT2016045E (pt) Forma cristalina de tigeciclina e processos para a sua preparação
JP2007512237A (ja) 固体及び結晶イバンドロネートナトリウム及びその調製方法
US20030144517A1 (en) Chiral fluoroquinolone arginine salt forms
JP2008539278A (ja) 結晶性ロスバスタチンカルシウム
JP2024512793A5 (enExample)
JPH0245634B2 (enExample)
SU1575941A3 (ru) Способ получени фармацевтически приемлемых эфиров 7- @ -/2-(2-амино-4-тиазолил)алкеноиламино/-3-цефем-4-карбоновой кислоты
JP2025520237A (ja) ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物
BRPI0702900A2 (pt) formas cristalinas da atorvastatina
JPH0324086A (ja) 結晶質セフェム酸付加塩およびそれらの製法
EP4182318B1 (en) Solid state forms of rucaparib salts
JPH02131483A (ja) ベンゾヘテロ環化合物
US20060293377A1 (en) Amorphous and polymorphic forms of telmisartan sodium
JP2022511392A5 (enExample)
EP4504717A1 (en) Solid state forms of zavegepant hydrochloride and process for preparation thereof
JP2025520238A (ja) ホウ素化合物のプロドラッグ及びその細菌感染の治療における用途
EP4482838A1 (en) Solid state forms of seltorexant
JP2008521874A5 (enExample)
WO2010022634A1 (zh) 新型乙二胺衍生物
EP1314726A1 (en) Novel ester or amide derivatives